688177 百奥泰
已收盘 03-26 15:00:00
资讯
新帖
简况
百奥泰最新公告：收到STADA支付的250万美元里程碑款
证券之星 · 18:10
百奥泰最新公告：收到STADA支付的250万美元里程碑款
百奥泰宣布与Intas制药就戈利木单抗生物类似药Bat2506达成印度独家商业化许可协议 深化战略合作
美股速递 · 03-23
百奥泰宣布与Intas制药就戈利木单抗生物类似药Bat2506达成印度独家商业化许可协议 深化战略合作
“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市
21世纪经济报道 · 03-09
“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市
百奥泰公布国际专利申请：“抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用”
证券之星 · 03-07
百奥泰公布国际专利申请：“抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用”
百奥泰(688177.SH)：BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书
智通财经网 · 03-06
百奥泰(688177.SH)：BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书
百奥泰(688177.SH)：乌司奴单抗注射液获上市批准
智通财经网 · 03-03
百奥泰(688177.SH)：乌司奴单抗注射液获上市批准
百奥泰（688177）披露2025年度业绩快报，2月26日股价下跌1.78%
证券之星 · 02-26
百奥泰（688177）披露2025年度业绩快报，2月26日股价下跌1.78%
百奥泰(688177.SH)2025年度归母净亏损3.36亿元
智通财经 · 02-26
百奥泰(688177.SH)2025年度归母净亏损3.36亿元
百奥泰(688177.SH)：达尔扑拜单抗注射液(BAT4406F)上市许可申请获得受理
智通财经 · 02-24
百奥泰(688177.SH)：达尔扑拜单抗注射液(BAT4406F)上市许可申请获得受理
百奥泰（688177）披露Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告，2月24日股价下跌0.68%
中金财经 · 02-24
百奥泰（688177）披露Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告，2月24日股价下跌0.68%
每周股票复盘：百奥泰（688177）授权BAT3306获最高700万美元
证券之星 · 02-08
每周股票复盘：百奥泰（688177）授权BAT3306获最高700万美元
百奥泰(688177.SH)与Avalon Pharma签署BAT3306(帕博利珠单抗)注射液授权商业化协议
智通财经 · 02-03
百奥泰(688177.SH)与Avalon Pharma签署BAT3306(帕博利珠单抗)注射液授权商业化协议
百奥泰（688177）披露关于变更保荐代表人的公告，2月2日股价下跌2.6%
证券之星 · 02-02
百奥泰（688177）披露关于变更保荐代表人的公告，2月2日股价下跌2.6%
每周股票复盘：百奥泰（688177）2025年净利预亏2.8亿至3.9亿元
证券之星 · 02-01
每周股票复盘：百奥泰（688177）2025年净利预亏2.8亿至3.9亿元
百奥泰（688177）披露2025年年度业绩预亏公告，1月27日股价下跌0.48%
证券之星 · 01-27
百奥泰（688177）披露2025年年度业绩预亏公告，1月27日股价下跌0.48%
每周股票复盘：百奥泰（688177）将召开临时股东会审议关联交易
证券之星 · 01-25
每周股票复盘：百奥泰（688177）将召开临时股东会审议关联交易
百奥泰（688177）披露归还临时补充流动资金的募集资金公告，01月22日股价上涨0.49%
证券之星 · 01-22
百奥泰（688177）披露归还临时补充流动资金的募集资金公告，01月22日股价上涨0.49%
百奥泰（688177）披露关于全资子公司与关联方签订建设工程施工合同暨关联交易的议案，1月21日股价下跌0.78%
证券之星 · 01-21
百奥泰（688177）披露关于全资子公司与关联方签订建设工程施工合同暨关联交易的议案，1月21日股价下跌0.78%
每周股票复盘：百奥泰（688177）获吉瑞医药250万美元里程碑款
证券之星 · 01-18
每周股票复盘：百奥泰（688177）获吉瑞医药250万美元里程碑款
百奥泰（688177）披露收到吉瑞医药里程碑付款进展公告，1月13日股价上涨1.26%
证券之星 · 01-13
百奥泰（688177）披露收到吉瑞医药里程碑付款进展公告，1月13日股价上涨1.26%
加载更多
公司概况
公司名称：
百奥泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-02-21
主营业务：
百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是创新药、生物类似药。
发行价格：
32.76
{"stockData":{"symbol":"688177","market":"SH","secType":"STK","nameCN":"百奥泰","latestPrice":20.5,"timestamp":1774508400000,"preClose":21.29,"halted":0,"volume":2524342,"delay":0,"changeRate":-0.0371,"floatShares":413999999,"shares":413999999,"eps":-0.8908,"marketStatus":"已收盘","change":-0.79,"latestTime":"03-26 15:00:00","open":21.28,"high":21.63,"low":20.4,"amount":52658100,"amplitude":0.0578,"askPrice":20.51,"askSize":135,"bidPrice":20.5,"bidSize":26,"shortable":0,"etf":0,"ttmEps":-0.8908,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":5,"adr":0,"adjPreClose":21.29,"symbolType":"stock_kcb","openAndCloseTimeList":[[1774488600000,1774495800000],[1774501200000,1774508400000]],"highLimit":23.42,"lowLimit":19.16,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":414080000,"isCdr":false,"pbRate":17.53,"roa":"--","roe":"--","epsLYR":-1.23,"committee":-0.407407,"marketValue":8489000000,"turnoverRate":0.0061,"status":1,"afterMarket":{"amount":0,"volume":0,"close":20.5,"buyVolume":0,"sellVolume":0,"time":1774510437558,"indexStatus":"已收盘 03-26 15:30:00","preClose":21.29},"floatMarketCap":8489000000},"requestUrl":"/m/hq/s/688177","defaultTab":"news","newsList":[{"id":"2622685631","title":"百奥泰最新公告：收到STADA支付的250万美元里程碑款","url":"https://stock-news.laohu8.com/highlight/detail?id=2622685631","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622685631?lang=zh_cn&edition=full","pubTime":"2026-03-26 18:10","pubTimestamp":1774519821,"startTime":"0","endTime":"0","summary":"百奥泰(688177.SH)公告称，公司近日收到STADA就BAT2506(戈利木单抗)注射液授权许可协议支付的250万美元里程碑付款(扣除银行手续费前)。该协议于2024年5月28日签署，授予STADA在欧盟、英国、瑞士等欧洲国家的独占商业化权益，首付款及里程碑款总额最高达1.575亿美元，并含净销售额两位数百分比的收入分成。目前，BAT2506已获欧洲EMA批准上市，商品名为Gotenfia，并已向中国NMPA、美国FDA、巴西ANVISA提交上市申请，正在评审中。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600034336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"1154213626","title":"百奥泰宣布与Intas制药就戈利木单抗生物类似药Bat2506达成印度独家商业化许可协议 深化战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1154213626","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154213626?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:47","pubTimestamp":1774266444,"startTime":"0","endTime":"0","summary":"百奥泰（Bio-Thera Solutions）近日宣布，通过与Intas制药达成印度独家商业化及许可协议，进一步拓展双方就戈利木单抗（商品名：Simponi®）生物类似药Bat2506的合作关系。该协议标志着两家公司在生物制药领域战略协作的深化，将为印度市场提供高品质的肿瘤免疫治疗新选择。\nBat2506作为戈利木单抗的生物类似药，其研发进展备受行业关注。此次合作将充分发挥Intas制药在印度市场的渠道优势，结合百奥泰先进的生物药研发技术，加速创新疗法惠及更多患者。协议条款涵盖Bat2506在印度的独家商业化权益，凸显了双方对产品市场潜力的共同信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2618113692","title":"“十五五”将谋划约千个紧密型县域医共体建设；先维盈 获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2618113692","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618113692?lang=zh_cn&edition=full","pubTime":"2026-03-09 08:07","pubTimestamp":1773014820,"startTime":"0","endTime":"0","summary":"这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！政策动向国家卫健委：“十五五”期间将谋划1000个左右紧密型县域医共体建设3月7日，十四届全国人大 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260309/c675145878.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260309/c675145878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["002653","LU1997244956.HKD","LU1146622755.USD","LU1655091616.SGD","LU2495084118.USD","BK0028","LU0405327148.USD","LU2097828557.USD","LU0405327494.USD","LU2148510915.USD","BK0188","LU1997245094.SGD","LU2289578879.USD","BK0183","LU1064131003.USD","LU2328871848.SGD","LU2097828714.EUR","LU1328615791.USD","LU1064130708.USD","LU2580892789.USD","BK0196","BK0060","LU1781817850.SGD","LU1820825898.SGD","LU2488822045.USD","LU1580142542.USD","BK0033","LU1997245177.USD","LU1255011170.USD","LU2097828631.EUR","688177","LU2097828474.EUR","600276","LU2580892862.HKD","LU2097828805.USD","BK0077","LU1969619763.USD","BK0012","BK0239"],"gpt_icon":0},{"id":"2617653589","title":"百奥泰公布国际专利申请：“抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2617653589","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617653589?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:44","pubTimestamp":1772833467,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示百奥泰（688177）公布了一项国际专利申请，专利名为“抗FRα抗体药物偶联物和VEGF拮抗剂在治疗肿瘤中的应用”，专利申请号为PCT/CN2025/116967，国际公布日为2026年3月5日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来百奥泰已公布的国际专利申请5个，与去年同期持平。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了3.49亿元，同比减13.34%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030700002602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2617684443","title":"百奥泰(688177.SH)：BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2617684443","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617684443?lang=zh_cn&edition=full","pubTime":"2026-03-06 19:11","pubTimestamp":1772795462,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研药品BAT8008联合BAT1006及曲妥珠单抗用于治疗HER2阳性晚期实体瘤的临床试验申请获得批准。BAT8008是百奥泰开发的靶向Trop2的抗体药物偶联物，拟开发用于实体肿瘤治疗。BAT1006是ADCC增强的单抗，其招募NK等杀伤细胞的能力更强，对肿瘤细胞具有更强的杀伤作用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411103.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：BAT8008联合BAT1006及曲妥珠单抗治疗晚期实体瘤获得药物临床试验批准通知书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2616312582","title":"百奥泰(688177.SH)：乌司奴单抗注射液获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2616312582","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616312582?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:28","pubTimestamp":1772526488,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 公告，公司近日收到了英国药品和健康产品管理局签发的关于Usymro上市批准通知。公告显示，BAT2206是百奥泰根据中国NMPA、美国FDA、欧洲EMA生物类似药相关指导原则开发的乌司奴单抗注射液，乌司奴单抗是一款靶向白细胞介素IL-12和IL-23共有的p40亚基的全人源单克隆抗体。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：乌司奴单抗注射液获上市批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2614290023","title":"百奥泰（688177）披露2025年度业绩快报，2月26日股价下跌1.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614290023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614290023?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:56","pubTimestamp":1772117772,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，百奥泰报收于23.24元，较前一交易日下跌1.78%，最新总市值为96.23亿元。该股当日开盘23.68元，最高23.74元，最低23.24元，成交额达4466.97万元，换手率为0.46%。近日，百奥泰生物制药股份有限公司发布2025年度业绩快报，营业总收入93,368.50万元，同比增长25.64%。归属于母公司所有者的净利润为-33,644.09万元，较上年同期减亏17,386.29万元。总资产226,665.76万元，较年初增长2.77%；归属于母公司的所有者权益37,153.08万元，较年初下降47.53%。主要原因为营业收入增长及经营亏损影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2614011827","title":"百奥泰(688177.SH)2025年度归母净亏损3.36亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614011827","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614011827?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:42","pubTimestamp":1772098972,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰(688177.SH)披露2025年度业绩快报，2025年度实现营业收入9.34亿元，同比增长25.64%;归属于母公司所有者的净利润亏损3.36亿元，上年同期亏损5.1亿元。业绩变动主要原因是公司营业收入持续增长：一方面公司积极拓展市场，阿达木单抗注射液(格乐立®)和托珠单抗注射液(施瑞立®)销售额较上年同期稳步提升;另一方面本报告期公司乌司奴单抗注射液(STARJEMZA®)于美国上市销售，授权许可收入及销售收入增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2613079727","title":"百奥泰(688177.SH)：达尔扑拜单抗注射液(BAT4406F)上市许可申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2613079727","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613079727?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:47","pubTimestamp":1771930078,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 百奥泰 发布公告，公司于近日收到国家药品监督管理局核准签发的关于公司在研药品达尔扑拜单抗注射液药品上市许可申请的《受理通知书》。截至本公告披露日，BAT4406F针对微小病变肾病/局灶节段性肾小球硬化适应症的一项II/III期注册临床研究正在全国多家三甲医院进行招募，该研究是我国首个针对该适应症的注册研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥泰(688177.SH)：达尔扑拜单抗注射液(BAT4406F)上市许可申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2613797244","title":"百奥泰（688177）披露Gotenfia（戈利木单抗注射液）获欧洲EMA上市批准的公告，2月24日股价下跌0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613797244","media":"中金财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613797244?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:41","pubTimestamp":1771929669,"startTime":"0","endTime":"0","summary":"百奥泰生物制药股份有限公司近日披露公告，公司收到欧洲药品管理局通知，其开发的戈利木单抗注射液已获EMA上市批准。BAT2506是依据NMPA、FDA和EMA指导原则开发的生物类似药，目前上市申请已获NMPA、FDA及巴西国家卫生监督局受理。该批准有望对公司长期经营业绩产生积极影响，但未来可能面临激烈市场竞争。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260224/32024193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["EMA","BK4081","BK0239","688177"],"gpt_icon":0},{"id":"2609261445","title":"每周股票复盘：百奥泰（688177）授权BAT3306获最高700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609261445","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609261445?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:04","pubTimestamp":1770491054,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，百奥泰报收于23.68元，较上周的23.46元上涨0.94%。本周，百奥泰2月6日盘中最高价报24.25元。本周关注点公司公告汇总：百奥泰与Avalon Pharma签署授权许可协议，将BAT3306在沙特与中东及北非地区的独占商业化权益有偿许可，可获得最高700万美元的首付款及里程碑款。百奥泰可获得最高700万美元的首付款及里程碑款，包括200万美元首付款、累计不超过500万美元里程碑付款，以及净销售额的两位数百分比收入分成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2608712278","title":"百奥泰(688177.SH)与Avalon Pharma签署BAT3306(帕博利珠单抗)注射液授权商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2608712278","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608712278?lang=zh_cn&edition=full","pubTime":"2026-02-03 21:27","pubTimestamp":1770125266,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百奥泰 发布公告，公司于北京时间2026年2月3日与Avalon Pharma签署授权许可与商业化协议。根据协议，百奥泰将公司的BAT3306注射液在沙特与中东及北非地区市场的独占的产品商业化权益有偿许可给Avalon，并可获得总金额最高至700万美元的首付款及里程碑款，其中包括200万美元首付款、累计不超过500万美元里程碑付款，以及净销售额的两位数百分比作为收入分成。帕博利珠单抗是一种人源化单克隆抗体药物，属于免疫检查点抑制剂。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2608609388","title":"百奥泰（688177）披露关于变更保荐代表人的公告，2月2日股价下跌2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608609388","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608609388?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:47","pubTimestamp":1770043636,"startTime":"0","endTime":"0","summary":"截至2026年2月2日收盘，百奥泰报收于22.85元，较前一交易日下跌2.6%，最新总市值为94.62亿元。近日，百奥泰生物制药股份有限公司披露《关于变更保荐代表人的公告》。变更后，公司持续督导保荐代表人为李胤康先生和任孟琦先生，持续督导期至中国证监会和上交所规定结束为止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200039559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2608070854","title":"每周股票复盘：百奥泰（688177）2025年净利预亏2.8亿至3.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608070854","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608070854?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:39","pubTimestamp":1769888351,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，百奥泰报收于23.46元，较上周的24.92元下跌5.86%。本周，百奥泰1月26日盘中最高价报25.31元。公司公告汇总：子公司拟投入8556.26万元建设永和创新产业基地。业绩披露要点百奥泰发布业绩预告，预计2025年全年归属净利润亏损2.8亿元至3.9亿元。营业收入预计为9亿元至9.7亿元，同比增长1.57亿元至2.27亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2606373875","title":"百奥泰（688177）披露2025年年度业绩预亏公告，1月27日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606373875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606373875?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:48","pubTimestamp":1769525297,"startTime":"0","endTime":"0","summary":"截至2026年1月27日收盘，百奥泰报收于24.8元，较前一交易日下跌0.48%，最新总市值为102.69亿元。该股当日开盘24.97元，最高25.12元，最低23.9元，成交额达6874.45万元，换手率为0.68%。近日，百奥泰生物制药股份有限公司发布《2025年年度业绩预亏公告》。本次业绩预告未经注册会计师审计。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700042268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2606322092","title":"每周股票复盘：百奥泰（688177）将召开临时股东会审议关联交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2606322092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606322092?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:06","pubTimestamp":1769281570,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，百奥泰报收于24.92元，较上周的25.07元下跌0.6%。会议审议《关于全资子公司与关联方签订建设工程施工合同暨关联交易的议案》，关联股东需回避表决，中小投资者单独计票。本次交易构成关联交易，已通过公司董事会、审计委员会及独立董事专门会议审议，尚需提交股东会审议。百奥泰于2025年8月20日经董事会批准，使用不超过1亿元闲置募集资金暂时补充流动资金，使用期限不超过12个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688177"],"gpt_icon":0},{"id":"2605879490","title":"百奥泰（688177）披露归还临时补充流动资金的募集资金公告，01月22日股价上涨0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605879490","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605879490?lang=zh_cn&edition=full","pubTime":"2026-01-22 22:44","pubTimestamp":1769093056,"startTime":"0","endTime":"0","summary":"截至2026年1月22日收盘，百奥泰报收于24.38元，较前一交易日上涨0.49%，最新总市值为100.95亿元。公司近日发布公告称，百奥泰生物制药股份有限公司于2025年8月20日召开董事会，同意使用不超过1亿元闲置募集资金暂时补充流动资金，使用期限不超过12个月。截至2026年1月22日，公司已将上述1亿元全部归还至募集资金专用账户，使用期限未超规定期限，并已通知保荐机构和保荐代表人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012200041231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2605483788","title":"百奥泰（688177）披露关于全资子公司与关联方签订建设工程施工合同暨关联交易的议案，1月21日股价下跌0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605483788","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605483788?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:33","pubTimestamp":1769005991,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，百奥泰报收于24.26元，较前一交易日下跌0.78%，最新总市值为100.46亿元。该股当日开盘24.4元，最高24.68元，最低24.09元，成交额达6143.59万元，换手率为0.61%。近日，百奥泰生物制药股份有限公司发布《关于召开2026年第一次临时股东会的通知》。本次会议将审议《关于全资子公司与关联方签订建设工程施工合同暨关联交易的议案》，该议案涉及关联股东回避表决，并对中小投资者单独计票。股权登记日为2026年1月30日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100041151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK0239"],"gpt_icon":0},{"id":"2604692549","title":"每周股票复盘：百奥泰（688177）获吉瑞医药250万美元里程碑款","url":"https://stock-news.laohu8.com/highlight/detail?id=2604692549","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604692549?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:14","pubTimestamp":1768680849,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，百奥泰报收于25.07元，较上周的25.51元下跌1.72%。本周，百奥泰1月13日盘中最高价报26.33元。协议首付款及里程碑款总额最高达1.10亿美元，包括850万美元首付款和不超过1.015亿美元的里程碑付款，另加净销售额的两位数百分比分成。公司近日收到吉瑞医药支付的250万美元里程碑款，实际到账金额扣除银行手续费。BAT2206已在美欧获批上市，商品名分别为STARJEMZA和Usymro，中国上市申请正在评审中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","09939","688177","BK0239","BK1161","BK1515"],"gpt_icon":0},{"id":"2603354638","title":"百奥泰（688177）披露收到吉瑞医药里程碑付款进展公告，1月13日股价上涨1.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603354638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603354638?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:29","pubTimestamp":1768314551,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，百奥泰报收于25.76元，较前一交易日上涨1.26%，最新总市值为106.67亿元。该股当日开盘25.44元，最高26.33元，最低25.44元，成交额达1.09亿元，换手率为1.01%。公司近日收到吉瑞医药支付的250万美元里程碑款，实际到账金额扣除银行手续费。BAT2206已在美欧获批上市，商品名为STARJEMZA和Usymro，中国上市申请正在评审中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","BK1515","688177","BK1161","09939","BK1574"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774540011474,"stockEarnings":[{"period":"1week","weight":-0.0792},{"period":"1month","weight":-0.1017},{"period":"3month","weight":-0.1005},{"period":"6month","weight":-0.2569},{"period":"1year","weight":0.1003},{"period":"ytd","weight":-0.0799}],"compareEarnings":[{"period":"1week","weight":-0.0323},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.0271},{"period":"1year","weight":0.1667},{"period":"ytd","weight":-0.0093}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"9397人(较上一季度减少0.89%)","perCapita":"44065股","listingDate":"2020-02-21","address":"广东省广州市海珠区国际生物岛螺旋二路18号","registeredCapital":"41408万元","survey":" 百奥泰生物制药股份有限公司的主营业务是创新药和生物类似药的研发。公司的主要产品是创新药、生物类似药。","listedPrice":32.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥泰,688177,百奥泰股票,百奥泰股票老虎,百奥泰股票老虎国际,百奥泰行情,百奥泰股票行情,百奥泰股价,百奥泰股市,百奥泰股票价格,百奥泰股票交易,百奥泰股票购买,百奥泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥泰(688177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥泰(688177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}